Drug Profile

TGX 007

Alternative Names: TGX-007

Latest Information Update: 11 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Trogenix
Class Antineoplastics; Gene-directed enzyme-prodrug therapies; Immunotherapies; Oncolytic viruses
Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin 12 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Glioblastoma

Most Recent Events

21 Apr 2026 Phase-I/II clinical trials in Glioblastoma (First-line therapy, Recurrent) in United Kingdom (Intratumoural) (NCT07346144)
27 Jan 2026 Preclinical trials in Glioblastoma in United Kingdom (Intratumoural) prior to January 2026
27 Jan 2026 Pharmacodynamics data from a preclinical studies in Glioblastoma released by Trogenix (Trogenix website, January 2026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com